## YIIATCTBO  3A  yfIOIIPEEA:I{HOOPMAIII4I4 3A KOPI'ICHIIKOT

## NILOTINIB PHARMA.SCIENCE I IJVTJIOTUTE'JdF  OAPMACAJAHC

150 mg KarrcyJra,  TBpAa 20lD mg KarryJra, TBpAa nilotinib

## Bunnrare,tuo npounrajTe ro qe,'roro yrrarcrBo  rrpeA Aa [oqHere Aa ro 3eMare  onoj len 6u4e.jrfui  roa coAp)KH Balr(Hrr IrHQopruraqulr  3a Bac.

- -Arco uMare AonoJrHrzTeJrHn npa[arba, nparuajre  ro Bauruor AoKTop uln  Sapuaqenr,
- -r{ynajre  fo oBa ynarcrBo.  Morxe6ra  r(e rpe6a  Aa fo [oBTopHo npoquTare.
- -Onoj JreK BH e nperuilraH  cavlo .Balr.  He ro 4anajre  Ha  Apyfu  ruqa. Toa 6t voxelo Aa  vM Harrrreru,  AypLr  14  AoKoJII(y  HI{BHrnre cI4MrIToMpI  ce ucrli xar&lt;o  Baurure,
- -[ororucy  4o6uere  6z.no KaKBr,r HecaKaHr,r gejcrna, noucy:nnpajTe  ce co Bamuor  AoKTop z,ru  $apuaqesr.  Toa rr4 BKryqyBa H etrre Mox(Hn HecaKaHH  4ejcrea  Ilrro He ce HaBeAeHI{ Bo oBa'ynarcrBo.  Bugere Lel  4.

## IIIro cogpxrr oBa yrrarcrBo

1. LLIro e Nilotinib Pharmascience'.n  3a rrrro ce ynorpe6yea
2. lllrc,  rpe6a  Aa  3Haere npeA  Aa  3erMere Nilotinib Pharmascience
3. Karco  Aa ro ynorpe6ynare  Niloti;nib  Pharmascience
4. MoxcHu  HecaKaHr4  aej crna
5. Kaxo  4a fo lryBare Nilotinib Pharmascience
6. CogpxnHa Ha rlaKyBarbero  Ii Ap)/rH  NH$oprr,laqrzrz

## 1. IIIro e Nilotinib Pharmascienc,e  H 3a rrnro ce ynorpe6yna

## IIIro e Nilotinib  Pharmascience

Nilotinib Pharmascience e JreK roj co4pxra aKrr{BHa  cyncrauquja  HapeqeHa  nilotinib.

## 3a urro ce Kopucrn Nilotinib Pharmascience

Nilotinib  Pharmascience ce Kopr{crr 3a neKyBa}be Ha eAeH Br.{A JIeyKeMIaja uapeueHa  xpoHHLIHa MueJrouqHa  neyxenauja co rro3lrrr4Beu  Oula4el$uja xpoMo3oM (Ph-lorurunua XMJI). XMJI  e KapuHHoM  Ha KpBTa  rrrro ro repa reJroro  Aa  npor,BBe.qyBa npeMHory a6uoprualuu 6etm KpBHI4 3pHIIa.

Nilotinib Pharmascience ce  Kopr4cru Kaj Bo3pacHH  H  ne4ujarpucxl't  [aqI{eHrH  co Hono4ujarnocrnrlupaHa  XlllJI urra naj naqueHru  co XMII xou sefte Hetuaar npu4o6unna o4 rperxoAHuor rperMaH nxnyuynajrta  ro imatinib.  Toj r4cro raKa ce KopI4crI{  xaj no:pacuu tz ne4ujarpzoxv nar\t4eHTLr  Ko?r  Ao)nr,rBeale  cepr{o3Ha HecaKaHH  4ejcrna  co nperxoAHt4or  rperMaH  14 He rvro)r(ar  Aa  rrpoAoJDKaT  Aa fo 3ieMaaT.

## Kano  QynrcrIHoHHpa  Nilotinib Pharrnascience

Kaj narpieurn  co XMJI, rrpoMeHara  ua  IHK  (reuercnuor ruarepr,rjan)  rpeAH3Bt4KyBa c]trH€ul  xoj ruy npeAH3BHKyBa  reJroro  Aa nportBe4e a6uopnaar:uu  6etu KpBHrr  3pHua.  Nilotinib Pharmascience  fo 6lorcupa  onoj curual, u ua rr:j Har{IrH ro 3anlrpa  co3AaBa}bero Ha oBHe KrerKH.

## MoHraropuHr'3a  BpeMe Ha rperMaHo'r  co Nilotinib  Pharmascience

3a epeue Ha rperMaHor tre ce Bpuar peAoBHH TecroBH, BKryr{urerH Ke rH cJreAaT: ir

- -KoJrnrrr4Hara  Ha KpBHpI 3pHua (6e;ru  xpnnu 3pHua,  upBeH reJroro  sa  na  ce BuAH KaKo ce roJrepupa  Nilotinib
- raHxpeacor u SyHrcqajara  Ha ItpHHor  4po6  Bo reJloro Nilol;inib  Pharmascienr;e.
- eJreKrporrr{Tu  Bo reJroro  (xa.nuyna, vrarueslrynr).  Tple  ce Ba)KHH -
- -HLBOTO  Ha rIeKep tI }'/A.CTL[ BO KpBTa.

<!-- image -->

Cpuennor pHTaM rte ce nponepyBav  co noMotrl HaMaLuv:aa  xoja ja MepI4 eJIeKTpkrqHTra aKTuBHocr Ha

cprlero (recr napeueH  ,,EKf").

Baurzor  AoKTop  peAoBHo fte ro oqeuysa  Bauero  JIeKyBaE'e u rte o4lyuu  gum rpe6a  Aa  npoAoJDI(I4Te Aa  3eMare Nilotinib  Pharmascience.  Aro su 6uqe KuKaHo  Aa. ro npeKr{Here  3eMa}bero  Ha onoj ler, Baruuor AoKrop  tre lpo4omrn  ga ja cre4r Baurara XMJI u Mo:xe Aa Bu rcaxe noBropHo Aa 3arloqHere co Nilotinib Pharmascience AoKonKy  Baruara  cocroj6a noKtDIq/Ba  AeKa roa e HeorxoAHo.

Axo uuare KaKBr{  6zlo npaua=,a 3a roa KaKo AeJryBa Nilc'tinib Pharmascience  uJIIr sorxro Bu e npenuilraHa Batur utu ua Baruero gere, nparuajre  ro Baruzor  AoKTop.

## 2. IIIro rpe6a Aa 3Haere rlpeA  Aa 3eMer€  Nilotinib  Pharrnascience

CleAere rr4 BHHMareJrHo cHTe  HHcrpyKIIHrr  Ha  AoKTopor.  Tue, Mo)Ke  Aa  ce pa3JII{KyBaar oA orllrlTnre uu@opnaaqzl4  coAp)KaHI{  Bo oBa yrlarcrBo.

## He reuajre Nilotinib  Pharmascience

- -aKo cre areprr,rqHr{  Ha :aunoru:au6  unu roja 6ulo oA ApyfHTe cocrojxu na onoj nen (uane4eHn no  4en  6).

Aro nruclure AeKa Mo)Ke Aa  6ugere  z[epfpILIHI4,  I(DI(ere M]/ Ha Bauruor AoKTop [peA Aa  3eMere Nilotinib  Pharmascience.

## Ilpegynpe4yBalr'a  Ir MepKIt  Ha rlperrla3JrlrBocr

Coneryaajre ce co Bauuor AoKrop  anu  $aprr.raqeBT npeA Aa 3eMere  Nilotinib Pharmascience:

- -aKo rrpeTxoAHo cTe rrpeTpneJre  KapAr{oBacKyJIapHH  HacTaHI{ KaKo lrlTo ce cpIIeB yAap, 6orKa  Bo rpaAare  (aHruHa),  npo6leuu co cHa6gynanero  co ripB Bo Mo3oKor (uosoueH  ylap) uttu npo6leuu co nporoKor  Ha KpB Bo Horara (nnaylurauwja) utu aKo HMare  $ar&lt;ropn  Ha pH3HK 3a KapAr{oBacKyJrapuu  6orecrn KaKo rxro ce BHcoK KpBeI{ npI{TI4coK  (xunepren:zja), guja6erec ulu npo6reMr{  co HIlBoro Ha MacHorHI4  Bo KpBTa  (Hapymynamaua tunugure).
- -aKo r4Mare cpqeBu HapymyBarba,  KaKo rrrro e a6Hoptuareu ereKTpl4r{eH  cHrHiL'I Haper{eH ,,npoJloHfuparbe Ha  QT  zurepnalor".
- -aKo ce JreKyBare co JreKoBH  Kor4 ro HaManyBaar  xcrilecreponor  Bo KpBTa (cralnnn), ultt ynujaar Ha orqyKyBarlura  Ha cprlero (anuEaplarvwlu)  utu Ha t(pHaor  apo6  (nuplere  l[pyru rreKoBH u Nilotinib  Pharmascience).
- -aKo cTpa.4aTe  oA HeAocTaToK  Ha KaJII4yMrulld  MarH*rryM.
- -aKo HMare HapylxyBalbe Ha IIpHHor Apo6 unu rlaHKpeacor,
- -aKo r4MaTe cHMnToMH KaKO rXTO Ce JrecHr,r MOApHHKI,I,  qyBCTBO  r{a 3aMop  HJIV HeAOCTaTOK Ha IAlv,B  prlrw  cre Ao)I(LIBeaJIe  rloBTopeuu  nnQexqun.
- -aKo cre nMaJre xupyprrrKa nporleAypa xoja nuyuyBa orcrpaHyBalbe Ha IIeJII4or x(eJIl/AHHK (rorarua racrperrouuj  a).
- -aKo HeKorau  cre IrMaJre  pmu  uoxe6u cera HMare r,ru$enquja co xerlarlrrnc E. Toa e 3aroa lxro Nilotinib Pharmasciellce  Molre Aa  ilpeAa3Br{Ka xeIIarHTIzc  E nonropHo Aa  craHe aKTHBeH,  ttlro Moxe Aa 6u4e  Sara-nHo  Bo HeKor,r cnyqa:a. llaqaenrnre ke 6ular eHul4arerub  MolllrropzpaHh oA HHBHH6T  .4oKTop  3a 3HarIH Ha oBaa ran$enquja ilpeA !,a  3alroqHe neKyBaH,ero.

Ano Heruro oA oBa ce oAHecyBa  ua Bac HItLr Ha Baurero  Aere,  riamere My Ha Bauruor AoKTop.

3a speN{e  Ha rexysalbero co Nilotinib Pharmascience

- aLo  {rriaru  HdHdAelrll4ihan.qdlfirau  Ha cpllero,  TeIIIKa  M)'cKyJIHa  cla6ocr vrv napatilzaa, Harra!.u 1ap uru rlegaftei"ti,udqrq""u'So$fllrero  pa3Mr{cnyBan,e HJI}I HHBo Ha 6y4uocr, BeAHaIrr KDKere My na B\fo-dr,.go;rlop  6#ha!ffi  roa Molr(e  ra6u1e  3HaK 3a 6pso pacuafarue Ha KrIerKI,{re  Ha rapurEn\cr,r\npadi1,W9/foM Ha rvrsa Ha ryMopor. flpujanenu ce perKu clry-uar4I{a cI'IHApoM !*l*.*ie Ha r'a3  a u  &amp;oadddffi.reHrlz  rp erl'rp a*vr c o n i I otin ib. -
- aKo ce oHecBecrr4Te  (ry6erre na cnecra) hrrrt vmare HerIpaBI4nHo  qyKalbe  Ha cpllero AoAeKa  fo 3 e M are o B-gjdrdk;;49:F:  *.."y.'  e My H a u3* Ti :\_T\_ iil 9 T:j 111"-1 y:I: ii : Ti: " : : T :: ceprao:r;d cp'qesa 6o4ecfi.IlpoAoJDxyBarbe  Ha  QT  IzH'repBzulor I4npI HenpaBI,uIHo  qyKabe  Ha cnuer/-Mox(e.Aa-{oriede,"\ ueuaAejua,.:,tlt'.,{9".iauery  ce, nesoo6uqaeHkr  cily.uaLr  Ha H eHa/eiuf c rr,r pr xaj ria  urq+rr'l\xo  H 3eM a"IIe N i I ot i n i b Ph a rtnasc  i enc  e. iii";d.*nt ri,quae -

- -aKo pa3Bzere 6omra utu uenpu;jarHocr  Bo fpaAHTe,  BKoqaHerocr  lalrpr cla6oct,  npo6lelru co oAelbero r.rJrn co roBopor, 6o.nrca, o6es6ojyeame vrpr  rryBcrBo  Ha cryA Bo eKcrpeMplTer, BeArrail Kalmere My Ha Bauruor AoKTop 6ugejku  roa Mox(e  Aa 6ule 3HaK sa KapAuoBacKyJrapeH  Ha.craH. Iprjaneun ce cepr4o3Hu  KapAHoBacKyJIaplnlalaacranu,  nxlyuyeajrtu npo6leuu co rrporoKor Ha KpB Bo Ho3ere  (nepu$epna  aprepl4cKa oKJIy3I{BHa  6o.recr), HcxeMrirrHa  cprleBa  6orecr u rpo6reuu  co cua64ynalr,ero  co KpB Bo Mo3oKor  (ucxerv;u'rua qepe6poeacKynapHa  6onecr) xraj naqueHrr4  Kor4 3eMarre  Nilotinib Pharmascience. Bauruor AoK'lop rpe6a Aa rc npoqeHu  Hr4Boro  Ha Macrr4 (t::zr:izgu) u rueftep Bo KpBTa rlpeA  Aa  3a.i.,oqHe rpelMaH  co Nilotinib Pharmascience u 3a BpeMe Ha JreKyBalbero,
- -aKo pa3Brrere  oroK Ha crariLiraria  lrJru parlere, reHeprurrr3upaH oroK Iaru 6p:o 3foJleMyBttie Ha TeJrecHara relr(IrHa, KOKere My Ha Baurror  AoKTop  6ugejku roa Mo)Ke  ra  6u1ar 3HaqI{ Ha cep?ro3Ho  3aApxyBarr,e  Ha reqHocru. flprajaBeHu ce Hesoo6zqaenr  cryqala Ha cepuo3Ho 3aAp)KyBarr,e  Ha rerrHocra rcaj nar{zeHTrz  rpervrpaHr  co nilotinib,

Arco cre poAriren Ha  Aere  Koe ce rpe'lupa co Nilotinib  Pharmascience,  Ka)Kere My Ha AoKToiror  aKo Heroja oA ropeHaBeAeHHTe  cocroj6u ce oAHecyBa  sa Baurero  Aere.

## .{eqa  u aA,oJecIIeHT[

Nilotinib  Pharmascience  e rperMaH  3a Aerla H a,qoJrecqeHTn  co XMJI. Heua uct' ycrno co Kopucrerr,ero Ha oeoj lex rcaj  Aeua  Ha Bo3pacr no1 2 roAHHr4. Henra  ucxycrBo co y'.i.lrpe6a Ha Nilotinib  Pharmascience  xaj Honoguja.rHoarurlupaHr,r .4erra  roA 1O-ro4uruHa Bo3pacr  u  ,rfpaHi4rleHo HcKycrBo  rcaj naqneuru noq\ 6-ro4uurua  Bo3pacr xou serte HeMaar Koplzcr oA nperxoAH'.;r{)T  TperMaH ra XMJ[.

Henou  Aeqa u aAoJrecrreHr?r  Kor{ ynorpe6ynaar  Nilotinib Pharmascience  Mo)r(e  Aa v*)ar no6aeeH pacr oA HopManHr{or.  [orropor  rte ro r;le4u  pacror npr{ peAoBHH nocerr{.

## Apyrn  JrenoBrr u Nilotinib  Pharmascjience

Nilotinib Pharmascience MolKe  4a uurep$epvpa  co HeKor{  Apyru  JreKoBH.

I4uQopnaupajre  ro Barur4or AoKTop atm  $aprvaqeBT roKoJrKy  3eMare,  FreoAaMHa  {','e 3eMaJre  I4JrI4 Mo)I(Fro e  Aa  3eMare Apyrt4  JreKoBr4. Osa oco6eHo  rrr BKryrryBa:

- -aHTVApLITMHIII4  -  Ce KOprrCTaT 3a JreKyBalbe Ha HerrpaBHJrHO  r{yxar6e  Ha Cpr{eTO;

i

- -chloroquine,  halofantrine,  clarithLromycin,  haloperidol,  methadone,  moxifloxacin  --  JreKoBrr Kon Moll(e  Aa  uMaar HecaKaHo  4ejcrno  Bp3 eneKTpr,IqHara  aKThBHocr Ha cprrero; i
- -ritonavir -  lex oA KJracara  ,,aHTurrporea3r.{"  tilTo ce Kopr4crrr 3a JIeKyBa}be ua XI4B;
- -ketooonazole,  itraconazole, voriconazole,  clarithromycin, telithromycin  ce Kopr4crr4 3a neKyBalbe  Ha rH$exqra  rz  ;
- -carbamazepine, phenobarbital,  phenytoin -  ce Kopr{crn 3a JreKyBarbe ua enu.rencuja;
- -KaHTapr4oH -  xep6a,reu  npor43BoA  rrrro ce Kopncru  3a JreKyBarbe  genpecuja 14  Apyrn  cocroj6n (ncro  rarca rro3Har  H KaKo Hyper,icunt  perforatum);
- -rifampiciri  -  ce Kopricrr4  3a JreKyrlarbe ry6epnylosa;
- -mida.zolam  -  ce Kopr.rcrr4:a  y6lax&lt;ynatle  Ha aHKcao3Hocra  npe.4 onepaqujara;
- -cyclosporine, sirolimus z  tacrolimus  JreKoBrr rcoz ja  norucuyBaar croco6riocra  ga ,,carvroo46paHa"  Ha re,Toro u ce 6opar [porHB  zuoelcqnu u uajvecro  ce Kop]rcrar  :ra Aa  ce cnpequ or$pname Ha rpaHcnlaHTnpa:eu opraHrz KaKo rrrro ce rlpHt4or  Apo6, c[rrlero I,I 6y6pe:ure; i
- -alfentanil  u fentanyl  -  ce Kopucrar  3a JreKyBalbe  Ha 6olxa r,r KaKo ce4arlaB rtpefi,  utu 3a BpeMe ua orepaqvj a HIru Menr4r\rzHcKl4  rlpoueAypr4;
- -Auxn4poepforaMuH  14 eproraMurr  -  ce Kopr,rcrar  3a JreKyBalbe  Ha  4elreHqaja;
- lovastatin,  simvastatin -  ce KopHorar 3a neKyBar+,e  BHcoKH HHBoa  Ha M -
- astemizole,  terfenadine, cisapride, pimozide,  quinidine, (ergc,tamine, dihydroergotamine). nAvr klir:l -Бери i
- warrann  -  ce KopHcTH  3a JreKyBa.rse  Ha HapyrryBarba Ha KoafyJr C, IIITO CE 3fpyrrryBabe Ha KpBTa  rzrrz rpov6o:a); -

Osrae rercoen rpe6a  Aa ce rzs6erHyBaar  3a BpeMe Ha rperMaHor  co 3eMare nercoj o4 oBlre JreKoBr{,  Baruuor  AoKTop  Mo}r(e  Aa  Br4 trpemrrrre Aro д

Aro seuare crarprH (ruu Ha JreK 3a HaMaJryBaIle  Ha xoJrecrepoJror  Bo

Bauruor .4oKTop vrrrr  $apnraqenr.  ,{oxonxy  ce KopHcrI.I  co oApeAeHH crurLrtr4) Nilotinib Pharmascience Mo)Ke  Aa fo 3roJreMr{  pr{3r.rKor oA MycKyJIHn  npo6leruu [oBp3aHI,I Qo crurr4rrv)  IIITo Bo perKr{ cvrya\r4v  Mo)Ke  Aa AoBeAe Ao  cepho3Ho pacnafame Ha MycKynure  (pa64oiuuo.nu:a)  urro p€yJITVpa  co ollrreryBaH,e  Ha 6y6pesure.

.{onomrureJrHo,  Kax(ere  My Ha Bauruor  AoKTop urn $aLplraIIeBT  IIpeA Aa  3eMere Nilotinib Pharmascience aKo 3eMare KaKBrr 6uro aHraqvqn, KovI ce JIeI(oBH rIporHB ropyilrl4l1a.  Oeple rexoeu rpe6a  Aa  ce 3eMaar oAAetIHo o.q Nilotinib Pharmascience:

- -HZ 6loraropu,  KoH ro  HawaJryBaur  npor{3Bo.4crBoro  Ha KIrceJIrrHa  Bo }I(eJIyAI{zxor. H2 6lorcaropu  rpe6a  Aa  ce 3eMaar npu6ruxuo  10  qaca  [peA I{ npu6luxuo 2  qaca  ro 3eMaEero r ra Ni lotinib Pharmascience;
- -aHTarlr4Arr KaKo rrrTo ce oHHe KOH COAp)I€T  [UIyMHHI4yM XHApOKCHA,  MarHe3I'IyM  XHApOKQI4A  I4 cuMerr4KoH,  nov ja Heyrpann3npaar BltcoKara KHceJIOcr Bo )I(enyAHHKor. Osue aHTaIIHAIa rpe6a Aa ce 3eMaar npn6luxrno 2  ,aaca  [peA I4nIr rpu6:rnnHo 2  qaca  no 3eMaFbero Ha N ilotinib  Pharmascience.

llcro rana, rpe6a Aa My KiD(ere na Baurnor  AoKTop  arco se(:e 3eMare Nilotinib Pharmascience  n Ba e npenurxaH  HoB JreK rrrro He cre fo 3eMzure [perxoAHo 3a BpeMe Ha rperMaHor  co Nilotinib Pharmascience.

## Nilotinib  Pharmascience  co xpaHa  u nnjalan

He eeuajre  Nilotinib  Pharmascience co xpana. Xpauara  rlIox{e  Aa ja nogo6pu  ancoptqnjara  Ha Nilotinib Pharmascience  H nopaArr roa Aa ro 3roJIeMI{ KoJluqecrBoro  sa Nilotinib Pharmascieuce eo KpBTa, rr,roxe6v  Ha rxrerHo  Hraso. He nnjre con og rpejn$pyr H He ja4ere  rpejnSpyr,  Toj nloxe 4a ro 3foJreMH KoJrur{ecrBoro  Ha Nilotinib Pharmascience  Bo KpBTa, uoxe6u  Ao  IrITerHo  HuBo.

## Epemeuocr  n Aoelbe

- -Nilotinib Pharmascience He ce [peropaqyBa  3r Bp€M€  na 6pemenocr  ocBeH arco e jauto HeonxoAHo.  At&lt;o cre 6perraeuu vrrw Mnclrprre AeKa  Iraorxe6N  cre, Ka)I(ere My Ha Barunor AoKTop rcoj rte pa3foBapa  co Bac Azrrru  Mo)Kere  Aa fo 3eMare oeoj ler 3a BpeMe ua 6petteuocra.
- -Ha lpeHrrre rcou 6u MolmeJre ga sa6peueHar  nM ce coBeryBa Aa Kopucrar  nzcoroe$unacua KoHTparlenqujaza  BpeMe Ha rperMaHor LI  Ao ABe HeAeJII{  ilo 3aBplllyBaliero  Ha rperl\4aHor.
- -He ce rperopaqyBa Aoerbe  3a BpeMe Ha rperMaHor co Nilotinib llharmascience  rI ABe  HeAenI4 rro nocJleAHara  Ao3a.  Kaxere My Ha Baurzor  AoKTop  aKo AoI4Te.

Ar&lt;o cre 6peueuu ulrvr 1okrre,  Mr,rcJrHTe  AeKa cre 6perreHu  Hrfir nilaHvtpure  Aa  HMare 6e6e, npaurajre ro Banuor AoKTop  Ianu  SapnraqeBT  3a coBer rlpeA Aa ro 3eMere oeoj ler.

## Bosene  H Kopucrerr,e MaruHHIr

[onolny  norryBcrByBare  riecaKaHu 4ejcrna  (narco urro ce BprorJlaBvr\avlrkr  BH3yeJIHI,r uapyuynama) co noreuqzjalHo  nmljauue  Bp3 cnoco6nocra  sa 6ez6e[Ho  Bo3erbe I4J1I4  KoplrcreTle  Ha xaxeu 5u,ro alrrru urrr4 MrarfvtHH  rro 3eMarbero  Ha oBoJ JIeK, Tpeoa  Aa  ce Bct3ApxI{Te oA oBHe aI(TItBHocrI4  AoAeKa He I'tcr{e3He  4ej  Craoro.

## Nilotinib  Pharmascience  coApll(u  JIaKTo3a

Oroj ne6 coApxtn  JraKTo3a (no:Hara H KaKo MJIeqeH nreftep). Aro Bauluor  AoKTop  BH KarKULII  AeKa r4Mare HeroJrepaHrluja  ua HeKolr urertepu,  noHraxrupajre  ro BilruNor  AoKrop  npeA  Aa ro lenlere osoj JIEK.

## Nilotinib  Pharm coAp)KII  HaTpIryM се

HarpI4yM  (23 mg) rc) Ao3a, [ITo 3Har{}t cyIurHHoKH  e ,,6e3 150-те Овој "tei ean (atoMa "bie Nmol ај SY,

о

- nib Pharmascience ко

Oeoj rex OHAKA I(AKO  ilITO BI.I K€DI(TLII  BANTUOT  AOKTOP Te ce co Bamuor  AoKTOp r.llu  Qapuaqenr. nrz Sapnraqenr. ce oka, користе год о pi!

KorKasa  rosa '  s x t&lt;\)? b Pharmascience

- [oromty  ne a уцотребувате Хи Ели дене 5

## Vnorpet[q Kaj eospacHz  rrauA

- -HonogujaruocrurlupaHrr rrarlr{eHTu  co XMJI:  IpenopauaHara 1,o3a  e 600 mg ua  4eH.  Onaa Aosa ce ilocrr4rlryBa  co 3eMarbe r{a  ABe  rBpAr4 KancyJrn oa 150 mg ABa narl{ Ha  AeH.
- -IIaqueHTH  KoH eerte HeMaar  x:opncr oA rperxoAHuor rperMau sa XMJI: llpenopauauara Ao3a e 800 mg Ha  AeH.  Onaa  Aosa ce ilocrlrfuyBa co 3eMar+,e no ABe  rBpApr  KancyJru o4 200 mg ABA  tlaTpr Ha  AeH.

## Vnolpe6a  rcaj  aeua u aAorecrleHTu

- -flo:ara Aa  eHa Ha Baruero 4ere  rte 3aBracr4 oA TeJrecHara ren&amp;rHa rr BprouHara  na Baurero  4ere. ,{or&lt;ropor  fte ja npecrraera ror{Hara  Ao3a  3a ynorpe6a u ke Bu Kax(e Kor,r }r KoJrKy KarrcyJrr4 Nilotinib PharmascienLco  A&amp;  My  AaAere sa Baruero  4ere. BnynHara  AHeBHa Ao3a  ruro rr,ry ja AaBa.Te  sa Baruero  Ae're  He cMee  Aa  HaAMr{He 800 mg.

Balraor AoKTop Mo)I(e  Aa rrpenuue roMarla  Ao3a Bo 3aBr{cHocr  oA Toa KaKo peafupare  Ha TpeTI4aHOT.

## ilocrapu;lyfe  (ua Bo3pacr og 65 rog.auu u nonerte)

Nilotinib P'harmascience  Mo)Ke  Aa ce x:opttcru  o4 ryfe Ha Bo3pacr oA 65 roAnHz u nosefte  Bo r4cra AO3a KaKO M 3A  4pyrLlTe  BO3paCHr4.

## Kora 4a 3€rMare  Nilotinib Pharmascience

3eme:re fu'rBpAHTe KancyJra:

- -ABanarH  Ha  AeH (npu6nrrxno  Ha ceKou 12 uaca);
- -uajlranrcy 2uaca no cenojaxpaHa;
- -rroroa nouexajre  I vac npe4 noBlopHo  4aja4ere.

Ano unaare nparxama  3a roa Kofa  Aa fo 3eMare onoj ,rer, Qapnraqenr'.  3enaarrero  Nilotinib Pharmascience Bo Lrcro 3anoMHr4Te  KOfa  Aa fH 3eMaTe  TBpAHTe  KarroynH. pa":ronapajre co Baruuor  .4oKrop  rzJrn BpeMe cexoj AeH rte su noMorHe Aa

## Kano Aa 3eMare Nilotinib Pharmascience

- -He eeuajre xpaHa 3aeAHo co rBpllr4Te KarrcyJru.
- -flporo,rrajre fr.r rBpAHTe Kailcyrt;a rleJrr4  co BoAa.
- -He ru oreopajre  rBpAI,{Te KancyJII{. Ano Bve uln Balrero  Aere  He Mo)Kere ga ja  rolrHere Uenara Kallcyna, rpe6a  Aa ce Kopl4crar  Apyrrr  JreKoBr{  co nilotinib HaMecro Nilotinib Phannascience.

## Ko,rrcy  AoJrro  Aa 3eMare Nilotinib  Pharrmascience

Ilpogolxer"e  co 3eMaILe  Ha Nilotinib Phannascience  ceroj AeH oHoJ'rKy  AoJrro  KoJrKy  ruro fte BH Ka)r(e Bauruor  AOKTop.  Oea e AoJrrorpaeH  TperMaH.  Bauuor AoKTop  peAoBHo rte ja cne4u Bauara cocroj6a 3a  Aa npoBepu  Aanv  rperMaHor fo AaBa nocaKyBaHrror  eQexr.

Banaor AOKTop Mo)I(e Aa  pa3MI{cJrLr  3a npeKr,rH  Ha rperMaHor co Nilotinib  Pharmascience Bp3 ocHoBa ua cnequ$uqHu KpuTeppryMu.  Axo zuare rrparrrar[a  3a roa KotrKy  AoJrfo Aa ro 3eMare Ni I  otinib Pharmascience, pa3r'o Bapajre,co B aruuor  AoKTop.

## AKo seN{ere noeefte  Nilotinilb  Pharmascience  orKoJrKy  rrrro rpe6a

Aro cre 3eIv{aJIe  noeei(e  Nilol.inib Pharrnascience orKoJrKy urro rpe6a, vilu aKo uexoj  apyr  cnyuajHo fH 3eMe Baruzre rBpAI,I Ka[cyJrI{,  B€,AHailr xoHraxrupajre  co AoKTop  uttu 6ot]HuUa  3a coBer. floxaxtere HM fo naKyBalbero rBpAr{ Karrcynu H oBa ynarcrBo :a ynorpe6a. Moxe  ra  6uAe Heo[xoAeH  MeAurIHHCKr4  TpeT'MaH.

## Axo :a6opaBr{Te  Aa 3eMere  l\ilotinib llharmascience

Arco nponylrrprre .4o3a,  3eMere  ja cle4uara  Ao3a cnopeA nJI Aa  HaAOMeCTVT9 3A npoilymTeHATA  TBpn;^a  Karr0yla.

## {orco"rrr&lt;y  rrpeKr{Here  Aa 3eMare Nilotinib Pharmascience

He npecrarryeajre  Aa fo croprlre roa. llpecraHorc 3eMare oeoi reK ocBeH axo Bauruor Bo  geMamero  Nilotinib Pharmascience  6es u

<!-- image -->

Be usloxyn a Ha pngvrK 3a BnonyBarbe  Ha 6olecra  IrITo Mo)Ke  Aa  vMa o{IacHH nocJIeAHIII{ rlo )KI{Bor. florpuxrere  ce Aa  pa3foBapare  co Baruraor AoKTop,  MeAI4III4HcKa  cecrpa ulunn  Qapuaqenr  AoKonKy pa3MHcnyBare Aa npecraHere  co 3eMarbe Nilotinib Pharmasciernce.

## Aro Banruor AoKTop nperopaqa Aa ro rlpeKlrHere  rperMarror  co Nilotinib Pharmascience

Baruuor.4oKTop  pe.qoBHo rte ro oqerryBa Bauuor rperMaH co cnequSuveu 4Iajaruocrur{Ku  recr: u fte oAJryqr4  aanu  rpe6a  Aa  npoAoDr(nre  Aa ro 3eMare onoj .nex. l\rco Ber 6IaAe narrcano  Aa  lrpeKnHere  co Nilotinib Pharmascience,  Bauruor  AoKTop  Iie npo4orxu  BHI{MareJIHo Aa ja c,'regu Baruara XMJI npe.q, 3a BpeMe  rr orKaKo fte ro npexuHere  Aa  3eMare NilotirLib  Pharmascience  LI Mo)Ke  Aa  Bh KrDI(e rroBropHo Aa 3a[oqHere co Nilotinib  Pharmascience AoKoJIK]'Baurara  cocroj6a  [oKDI(yBa  AeKa roa e HeollxonHo.

.{oxonny  r{Mare  Apyrrz  rrparxatla Bo BpcKa co yrorpe6ara  ua onoj JIeK, KoHcyJlTupajre  ce co Balruor AoKrop  Izrn  Sapuaqeer.

## 4. Moxnu HecaKaHH 4ejcrna

Kano u cHTe Apyfr{  JreKoBtr, oeoj ren Mo)I(e Aa  npe.qI43BHKa  HecaKaHI{  gejcrea,  ra norcpaj Toa utro He fH Ao6r,rBa cexoj. Ioseftero  oA HecaxaHrare  4ejcrna  ce 6.irara  Ao  yMepeHI4  I4 feHepaJlHo  rte HcqesHar rro HeKoJrKy  AeHa AO  HeKOJIKy HeAenI,I oA TperMaHor.

## Henon HecanaHu gejcrna  Molne  Aa 6u1nr cepuo3Hl{.

- -3Har{z  Ha MycKyJIHo-cKenerHa  6olna: 6o:rxu  so  grro6oBl'ITe  I'I MyoKyJrHTe
- -3Harlu Ha cprIeBH  HapyrxyBarba:  6olra uru uenpujarHorlr Bo rpaAplTe,  BI4coK  HJIII HH3oK  KpBeH npvrucoK, HerrpaBHJreH cprreB pr{TaM (6pz nnu 6aeeH),  nannvrar\r4vl  (uyncrno ua :a6psaHo qyKabe ua cpuero), HecBecrprqa )  cvHa npoMeHa na 6ojara Ha ycHhre, ja:uxor HJIII Ko)I(ara
- -3HaIIu Ha aprepr{cra  6lona4a: 6orna, uenpajarnoct,  cla6oc.r uJrI{ fpr{eBI'I  Bo Myc,KyJII4'te  Ha HO3eTe,  IITO MO)r{e  Aa ce AoJlx(H  Ha HaMaIreH npoToK Ha KpB,  qI4peBH  Ha Ho3eTe  flJII4 paIIeTe KoH noJreKa sapaclyBaar nJrH BoonrrlTo He 3apacHyBa€tr  H sa6erexilHBll npoMeHz no 6ojara (cuunno unu 6tenuto) utu reMneparypa  (na4erse) r{a 3acefHarara Hofa, paKa, rpcru Ha Ho3ere I4JrH palleTe
- -3HaIIr4  Ha HeAOBOJIHa aKTHBHOCT  Ha THpOHAHaTa  )KIe3Ait: 3foneMyBalr'e Ha TeJlecHa:fa TelI(IIHa, 3aMop, ry6en,e  Ha Kocara, MycKyJIHa  c;ra6oct,  rryBcrBo  Ha cryA
- -3HarIH Ha xunepaKTr4BHa rupouAHa  )IoIe3Aa:  :a6p:auo,  t{yKarbe  Ha cpllero, HcrtaKHaru orlu, ry6erue Ha re)I(HHara,  oroK Ha npeAHlror AeJI  Ha Bparor
- -3Harlpr Ha HapymyBalba  Ha 6y6pezure  vlrr4 ypI4HapHI,Ior rpaKT: )KeA, c)rea Ko)I(a, pa3ApiBnrrBocr,  TeMHa  ypvHa, HaManeHa  KoJrlIqpIHa Ha yprlHa,  TeIrIKorHI4 u 6olxa npu MoKpeEe,  nperepaHo  rryBcrBo  na norpe6a 3a MoKpelbe., KpB Bo ypr4Hura, a6nopuartua  6oia na ypnHara
- -3Haqu Ha Br4coKo HIrBo Ha rxeKep Bo KpBTa: rlpeKyMepHa )I(eA, BllcoK  I43JIe3 Ha ypr4HA, 3foJIeMeH  arlernr co ry6eme  Ha re)KuHara,  3aMop
- -3Haqu Ha BepTI4ro: BprofJIaBIrI{a  UrH syBcrBo Ha BpTe}be
- -3HaUH Ha r1aHKpeaTvTuc',  cvtlHa 6olxa Bo ropHHoT (.p"le" nlu les) a6Aoueg
- -3Har-(H Ha HapyrxyB arba Ha Kox(ara:  6oruu  qpBeHI,I  rp'yrKrl,  6olma Ha Ko)Kara,  ITpBeHVJIo  Ha KO)KaTa' JIyneH,e  I{nil ilJIyCKaBIIII
- 3HaqH Ha 3aApxyBal6e  Ha BoAara: 6pso:rolelryBalbe Ha reJlecHara parleTe, fny)KAoBI,ITe,  CT AIIAIaT  a Hnu JIHIIeTO TeXVHa, OTeKyBaH'e Ha -
- 3HaUrr Ha MAfpeHa: auIt]Ha  uIaBo6oJIKa  qecro  npHApy)I(eHa  co TIYBCTBHTCTHOCT fa.4erbe,  nonpaftame  u -ина
- 3HAUI,I HA H BTa: TpecKa, JIecHI4  MCTApHHKI4  unu ueo6jacHero  KpBaperbe, TEIIIKH ,jacnera  cra6ocr Hi -ил pede
- 3HaUr4 crrcTeM: cJraoocT wnh napanv3a Ha eKcTpeMuTeTHTe  HJI|4 I14IIETO, IXTO HE Tpenepe rura rlano6oJrKa,  rJreAaEe,  qyBcrBo  u[tv cilyruarre pa6oru BHAor, ry6ebe Ha cBecra, noH$y:uja, Ae:opneHraquja, OorKa r4Jrr4 BKorlaHerocr Bo fipcrHTe Ha patlere I{ Ho3ere / | -H " Нафушувања fa ндрвијот И ¥ Мени 80 ,
- 3Haqtl  H H oonKa BO eAeH  AeJr  OA TeJIoTo =~ we рутчу и ЊЕ ВбнА ток
- 3Harlr{  Ha yBaBa: oTelKHaTo  AH[leIle ula  6oluo AI4IIreBe,  KalIJIHua, -

ore)I(Haro AHIIrerbe  co LrIlH 6es rpecxa, oreKyBarbe Ha cranarrara  HJII{ Ho3ere

- -3HaIIH Ha facrpot4HTecrnHilJrHr4  HapymyBawa:  a6gorvtvnalrHa  6olra, raAelr,e,  noapaftane  co KpB, IIpHa  IZJII4 KpBaBa  croJlrlqa,  3arrex, xeroBzHr4, peQlyxc  Ha xeryAorrHa  KuceJrprHa,  oreqeH CTOMAK
- -3Haqu Ha HapyruyBalla Ha IIpHIror  Apo6: )Korra Ko)(a H orrv) rarleH,e,  ry6eme  Ha afierrT, reMr{a  6ojauaypr{Ha
- -3Hatlu  ua uu$erquja na rrpHlror  Apo6:  roBropyBarbe  (peaxrunzparbe  Ha uu$er&lt;quja  co xenarnruc B)
- -3Hal-llr  Ha eJIeKTpoJrHTeH  guc6ataac: faAerbe,  ore)KHaro  AHlreBe,  HenpaBVJIHo  r{yKarr,e  Ha cpllero, 3aMaryBarbe  Ha ypprHuta. 3aMop  ulutu nenpajarirocr  so srro6oBr{Te rroBp3aHv  co a6uopualHla pe3yJITarH oA KpBI{H  TecroBH  (xaxo  urro ce Br{eoKrr  HHBoa  Ha KaJrHyM,  ypkrrrHa KrrceJruHa ra  $ocQop  kr Hrrcnrr HHBoa Ha xa,rqnyu)
- -3HaqI{  Ha OqHLI HapyIXyBaEa:  HapyrxyBarr,a Ha B}rAoT  ercny,ryaajupr  3aMaTeH nu4, 4nojHo rJle.4albe, uilu sa6etexaHu  6,re0oqr{ Ha cBeTJrrrHa,  HaMaJreHa  ocTpnHa  urz ry6erre Ha BHAoT, KpB Bo orII,ITe, 3foJIeMeHa  r{yBcrBlirerHocr  Ha oLIHTe Ha cBerruHa,  6onxa Bo oqI,ITe,  qpBeHHJIo, qerrrame  vIrH krprTarl4ia,  cyzo oKo, oroK IrJrI{  qelrarbe  Ha oqHure  Kaltaqn

KoHrarcruprajTe  fo BeAHaru Barruor  AoKTop axo sa6erexuTe Henoe oA norope HaBeAeHHTe  HecaKaHr4 4ejcrea.

## Henou HecaxaHu  4ejcrea  cg MHory  qecrn  (nroxe  4a  ce nojanar raj nonerte  o4 1 na 10 nurla)

- -rJraBo6olxa
- -gujapea
- -HeAocraroK Ha euepruja
- -6orna Bo MycKyJrrzre
- -qe[Iarbe,  ocHII
- -ranerse
- -nonpaftame
- -KoHcrnnayuja
- -ry6eru,e Ha Kocara
- -6olra Bo eKcrpeMr{Te'I'HTe,  6o,rnu Bo KocKHTe  a 6olxa no 'p6eror npn npeKr.rH Ha rpcrMaHOT co Nilotinib  Pharmascierrce
- -:a6asyBarbe  Ha pacror raj Aeuar,a H aAoJrecrleHTr{Te
- -nHQer&lt;qzja  ua fopHl4or  pecnvparopeH TpaKT exny.rynajrtu  6olrcz Bo rpJroro r4 TeqeH,e uJu.r 3ATHAT  HOC. KHBAII,E
- -HncKo HHBo  Ha KpBHH  3pHrla (qpsenn 3pHua,  rpou6oqurz) zln xenouo6uu
- -BHcoKo HHBo ua 6utnpy6vH Bo KpBTa  (rpynnquja  Ha r{pHzor  Apo6)
- -BHcoKo Hr{Bo Ha nnila3a  Bo KpBTa.  ($yuxquja ua naunpeacor)
- -Br.rcoKo  Hr.rBo  Ha arraHLrH  aMr{HoTpaHc$epasu  Bo KpBTa  (eHsauu  Ha rIpHaoT  Apo6)

## Hexou HecaKaHH  4ejcrna  ce  qecrn  (naoxe  4a ce nojarar na 1 o4 10 nzqa)

- -a6gotvtnlnaJrHa  6orrca, uelpujaruocr  Bo croMaKor nocre ja4erre, HaAyeHocr, oroK rzJIrI Ha4yeHocr  Ha a6AoMeHor
- -[HeBMouuja
- -6olxn Bo KocKHTe,  fpr{eBa Bo MyoKynHTe
- -6olrca (nxnyuynajfta  6olxa  no nparor)
- -cyBa Ko)Ka, aKHH,  HaMaJIeHa  qyBCTBHTeJIHOCT Ha KO)I(aTa
- -HaMa,JIyBalLeHJIII3lOtIeMyBaH,eHaTeneCHaTaT9)KLIHA
- -Hecorlt,rrla,Aenpecuja,aurccuo3Hocr
- -HortHo  rroreH,e,  npeKyMepHo  norelLe
- -o[Ir]To rro[ro  qyBcTBo
- -KpBapeBe oA HocoT
- -3Har,lu  Ha fl4xr: 6olnu u orerreHu  srro6osu
- -HeMo)KHocr  Aa ce ilocrr4fHe  r,rJrr4 oAp)ru  epercquja
- -CHMnTOMH CrUqHr4 Ha rpHII
- -6poHxnrrc
- -6orrcrz  Bo rpJroro
- -6olxa Bo yBoro, cryilrHlr 3Byrlu (na np. 3ye6e, 6puueme)  so asnop (ncro raKa HapeqeH  rrEnrEr;yc)

m,

<!-- image -->

- xeMopoHAlr -
- TerrKrl MeHcTpyaIHH  IIHICIyCI4 -
- qe[rarbe  Ha  QolHKyrkrre  Ha KOCara -
- op aneH ulrv B afr4}{areH .{p  o3.4 -
- 3HaIIH Ha KOHjyHKTI4BVTTLIC:  HCqeAOK OA OKOTO  CO qe[IaILe, IIpBeHHJIO  Il OTOK -
- vpvTa\r4ja  Ha oqHTe, upBeHLI  OqH -
- 3HarIU Ha xHIIepTeH34jai  BI,ICOK  KpBeH  IIpIITIICOK,  ruIaBO6OIKa,  BpTOTJIaBZIIa -
- 14cnt{parbe -
- 3HaqH Ha nepv$epHa aprepr{cKa oxJry3r,rBHa  6oJrecr: 6oma, Henpujaruoct,  c;ra6oct ulllr tpr{eBr4  Bo MyCKyJTHTe Ha Ho3eTe,  IITO MO)Ke  Aa  Ce AOJI)KH  Ha HaMaJIeH  IIpOTOK  Ha KpB,  rII'{peBU Ha Ho3ere r{Jrr{ pauere  Kor,r  rroJreKa  3apacHyBaar  I4JITI BooIrIrITo  He 3apacHyBaar  N sa6erexilI.IBu npoMeHrr no 6ojara  (cnuulo unu 6nelusto) unrz reMrletrarypa  (na,4eme) Ha Ho3ere HnI4 pallere (lroxuu 3HarIH Ha 6lorcnpana  aprepaja Bo 3acerHarara rflofa, [pcll4 Ha Ho3ere unu paqere) -
- orexHaro  llzlxelbe  (Itcro raxa HaperleHo  4ucnuea) -
- paHH BO yCTaTa CO BocntuteHHe  Ha He[UaTa (ucro TaKa llapeqeHH CToMaTHTHC) -
- BHcoKo HHBo  Ha aMr4nasa Bo KpBTa ($yuxquja na laurpeacor) -
- Br4coKo  HI4Bo Ha KpearI4HHH  Bo KpBTa  ($yHxqzja  Ha 6y6peszre) -
- BrrcoKo  HHBo  Ha aJIK€uIHa  $oc$ara:a  HJII4 Kpearun  $oc$oxrzua3a  llo KpBTa -
- BHcoKo Hr4Bo Ha ac[apTaT aMl,IHoTpaHc$epasu Bo KpBTa  (enszva Ha qpHHoT  Apo6) -
- Br{coKo Hr{Bo Ha faMa rJIyTaMHJITpaHcSepa3I4  Bo r&lt;pnra ('eu:uMu Ha IIpHI4oT  Apo6) -
- 3HauH Ha JIeyKoIIeuuja utu Heyrponenaja: HHcKo HI{Bo Ha 6elu rpnuu 3pHqa -
- 3foJreMyBarbe  ua 6pojor Ha rpona6oqlzrpr  rtlru 6eln npnuu KJIeTKI4 -
- HHcKo HHBo  Ha MarHe3tryM, KiIaLtyM,  HarplryM, Karulrylv nna  $octlrop  Bo KpBTa -
- 3roJreMeHo  HIrBo Ha KzuIt4yM,  KaJIIII{yM  rznz  Soc$op  Bo llpBTa -
- BacoKo HrrBo Ha Macru Bo KpBra (nrnyuynajrtu  xolecrepol) -
- BHCOKO HHBO Ha ypvqHa  KI4ceJIuHa  Bo KpBTa -

## Herou HecaKaHI{  4ejcrna  ce IIoMaJIKy  qecTl{  (nloxce  4a  ce nojanar na I oA 100 mqa)

- -zulepfrEja(npeocerJluBocrHaNilotinibPharmascience)
- -oyBaycra
- -6olxa  Bo fpaAHTe
- -6om&lt;a utm uenpujarHocr  Ha crpaHara  Ha reJloro
- -3IOJIEMCH AIIETI4T
- -3foreMyBalle  Ha fpaAVTe  naj uaxnre
- -rzu$erquja  co xepnec  BITPYo
- -BKOI{AHETOCT  HA MYCKYJII4TE  I,I 3INO6OBHTE'  OTEKYBAIT,E  HA 3INO6OBVTE
- -qyBcrBo  Ha npoMeHa  Ha reJrecHara  reMneparypa  (exrryuynajftrz  .rvscrno  Ha ronJIHHa,  qyBcrBo Ha cryA)
- -Hapy[eHo  rIyBcTBo  3a BKyc
- -qecTo  MoKperbe
- -3HaqH Ha Boslliule]H4e  Ha cJry3HI4IlaTa  Ha )I(enyAHltIKoT:  a6Aouusalua  6onKa, faAerbe' norpartau'e, aujapea,  HaAyeHocr  sa a6Aouenor
- -qncra Ha KolKara,  I{creHqyBalr,e uru :a4e6elynarrce ua Ko)I(ara, Hajog4aleueHuor cloj na Ko)Kara, o6e:6ojyear+,e  Ha Ko;Kara saAe6eryearr'e  Ha
- -ry6er+,e ua ntenaopujara
- -3Ha\L,t Ha ncopr.rja:a: eaAe6ereHz  AaMKI{  Ha I{pBeHa/cpe6peua  xoxa
- -3foJIeMeHa  qyBcrBI4TenHocT Ha KO)I(ara Ha cBeTJIITHa
- TeurKoTI{H  CO CJIyXOT -
- yprHapHa  HH
- BOCIIZIJIEHHE Haper{eHo eHTepoKoJItlTI4cJ
- AH'LIIEH
- oron Ha 6
- CLl  MIITOMII o6u.IHo H Hose  (HeoAorHszL  rter6a Aa ce ABIDKI'I AeJr  oA Teroro, 1A"IHL4  CeH3A\r4V) He
- 3HAIIH  HA OTE)KHATO rpaAr{re, noKaqena/srorleMeHa  cpIIeBa  Qper$euquja, AlrrletI,e -с BO ди
- arcqec) nu$exqzja Ha
- OpaAaBXrIa Ha Ko)Kara
- 3roJreMyBarr,e  Ha oApeAeH  BlrA H,a 6elu xpnuu 3pHIIa (uapeueHu eosnnosunu)
- 3Haqu Ha ruu$oneuzja: uacHo I{IdBo Ha 6eru xpnun 3pHlra
- BucoKo  HHBo Ha rraparapor4Ae.H xopMoH Bo KpBTa (xoplroH  xoj ro peryJrnpa HHBoro  Ha KanrIHyM  ra  Soc$op)
- Bl,rcoKo HHBo  Ha raKTar  AexHApofeHa:a (eH:uv) Bo KpBTa
- 3HarF Ha Hr.rcKo HLrBo  Ha urertep Bo KpBTa:  raAerbe,  Irorerr,e, cra6oct, BproDIaBI4ua, TpeilepeH,e,  ruaeo6orrca
- 4exz4paqrzja
- a6Hopua,rHo  HHBo Ha MacHorHH Bo KpBTa
- HeBoJrHo  rpecelLe  (uc'ro rana HapeLreHo  rpen,lop)
- Te[r KoTr4H  CO KOHrIeHTpHparbe
- uenpujarno  u a6nopnarHo  rryBcrBo  rrpr,r  Aoilup  (ncro  raxa HapeqeHo  4u:ecresuja)
- 3aMOp  (ucro raxa HapeqeH  vrsHeluomreHocr)
- TTYBCTBO  HA BKOI{AHETOCT  HJII{ T]PHEII,E BO NPCTI'TE  HA  PAIIETE  I'  HO3CTC  (UCTO TAXA HAPEIIEHA nepz$epua ueeponaruja)
- ilapuil43a ua roj 6uno naycrcyJr  Hil Jrr4rlero
- rrpBeHa  AaMKa so 6erKara  Ha oKoro npeAu3Br4KaHa  oA r{crryKaHH KpBHt4 caAoBI4  (ucro raxa HapeLreHa  xoHjyHrcaea,rua  xerroparzj  a
- KpB Bo oquTe (ucro raxa HapelreHo ouuo npnapene)
- npn'ratpja Ha oqhre
- 3HauH Ha cpueB yaap (ucro raKar HapeqeH  Mr4oKap.qeu  auQaprc):  Heuagejua 14 ocrpa 6onxa eo rp alrlT e, 3 aMop, HenpaBHJrHo  r{ytKarb  e Ha cp qeTo
- 3Haqz Ha cprreB  uyM: 3aMop,  Heupujaruocr Bo rpaAHTe,  3arueMereHocr, 6oma Bo fpaAr{Te, TZUIIIHTAIIHH
- ra6nqsa rzHQenqnja Ha crailarara
- 3Hau,H Ha cprleBa cla6ocr: orex(Haro  Ar4rrrelle,  orelr(Haro  Al4rrreme  npu JrerHyBarbe, oTeKyBaH,e Ha crarIiIJIaTa aJII4 HO3eTe
- 6olr.a  3aA KocKara  ua gojxara  (ucro rana HapeqeHa  nepuKapAr4Tlrc)
- 3HarI,H  Ha XUnepTeH3r.rBHa  KpH3a: CprJrHa  HasO6OrKa, BpTOfraBUrIa, raAeF,e
- 6o,rra u cla6ocr  Bo Ho3ere npeAu3BrzKaHr.{ oA oAerbe (ucro raxa HapeqeHa uHTepMpITeHTHa x,.ray4uraquja)
- 3HaqH Ha CTeCHyBarbe Ha apreplrvre  Ha eKcTpeMilTerr4Te:  Mo)KeH BkrcoK KpBeH rrpr4TrrcoK,
- 6olurz fpr{eBu  Bo eAHuor r4Jrpr  4Bara  KoJrKoBrz,  6yronure  r4Jrr4 MycKyJIr4Te  Ha norKoJreHrrqara nO OApeAeHLI aKTI{BHOOTH  KaKo IIITO Ce OAe}I'e  pIIu  KaqyBABe IIO CKAJII"j,  BKOqaHeTOCT  kIItkl cla6ocr Ha Ho3ere
- MoAp'rHr(H  (uaro ue cre ce noape4ule)
- MacHH HacJrafu Bo aprepr4r4Te  r{or4 Mo)Kar  Aa  npeAr43BhKaar 6loraAa  (ucro raxa HapeqeHa aprep14ocKrepo:a)
- 3Harru Ha Hr43oK KpBeH npuTlrcoK (ucro raxa HapeqeHr.r xuroreHsuja):  :arueuereHocr, BpTOfraBHrla HJIH HeCBeCTHTIa
- 3Haur4 Ha rryJrMoHaJreH  eAgM: ocranyBalLe  6e::Aas
- 3Harlh Ha rr,TeBpaJreH H3JII,TB: co6upame  reqHocr nonaeiy  cJloeBare Ha rKHBoro Irrro fH o6roxyeaar  6elnre Apo6onu  u rpaAHara rrpa3HuHa  (xoja,  4onoJrKy e re[IKa, lroxce  4a  ja HaMaJrr4 cnoco6nocra  Ha cprlercr  {a [MrIa  xpn), 6orxa Bo rpaArrre, KaITIJI]tqa,  uxame,  6pso .trulleILe
- 3Harrn Ha lrHTepcrugnjatma  6eno4po6Ha  6orecr: KarrrJrurla, ore)I(Haro AI-t[Ie]be,  6olHo AHlxeTL'e
- 3HauH Ha flJreBpnTcrca 6o,'rKa: 6olrca  Bo rpaAhre
- 3Har  lr{  Ha nJ.r  eBpHT  : Karl]u4r\a,  6o.rrHo  AHIrI  erle
- panaB fJrac
- 3HaIIu Ha rD/nMoHanHa  xunepT,eH3gja: BIlcoK KpBeH ilpHTHcoK AP06oBH 6elure B „ајудерииј а
- orexHaro  nHlxelbe
- qyBc'rBHTerH  n la6n
- sHaqrz Ha BocrilrreHue  (ncro raKa HapeqeHo rr4HrnBrrrnc):  rcp
- 3toJIeMeHn HeIIqa
- BHcoKo HHBo Ha ypea Bo r&lt;pma  ({rynx4ujana  6y6pe:vre)

<!-- image -->

- npoMeHa Ha npoTel{Hr4Te BO KpBTa (HI4cKo  HHBO Ha rJIoOynI4HI{ IdI[Id npHc)ycTBO  Ha napaflporer,rH) -
- BucoKo HHBO Ha HeKoHjyrlpa]H6urrr4py6plH BO KpBra -
- B}ICOKO HI'BO HA TPONOHVHH BO KPBTA -

## Henon HecaKaHIr  4ejcrna  ce pernl{ (uoxte  4a  ce nojanar rcaj 1 o4 1.000 rvqa):

- -rlpBeHuto  ululu oroK tr eBeHTyzurHo  Jrynene  Ha AJIaI{KIlre  H crarlilfiara  (r.u. cI{HApoM  Ha parca-cranalo)
- -6pagaBHIIH  Bo ycrara
- . IIYBCTBO  HA CTBPAHYBAIbE HJIII BKOqAHETOCT  BO IPAAHTE
- -BOCfiareHHe  Ha rupot'lAHara  )ru1e3Aa (ucro  rara HapeqeHo  rupora4tlruc)
- -Hapy[eHo  HJIH AenpecHBHO  pacrIoJIo]I(eHVe
- -3Harr6 Ha ceKyHAapeH  xr4nepflaparr4pou1krcaM:  6onKu B,o KocKZTo  H 3fJIo6oBI4Te,  [t)eKyMepHo MoKperbe,  a6  Aovugantla  6olna, cla6oct,  3aMop
- -3Harrlr Ha crecHyBame Ha aprepur4Te Bo Mo3oKor: ry6erre Ha BuAor AeJIyMHo.uJII4  Ha ABere oun,  4nojno  fJleAarbe, BprorJraBr4rla  (uyncrno na epreme),  BKorraHerocr  I4JIv neqKaH'e, ry6eme Ha Ko opArrH  arluj  a, Bprorra  BI{ua anu xou$ysuj  a
- -oro1 Ha Mo3oKor  (naoxrna  ruaeo6oma  ulutu npoMeHlr Ha MeHTaJII{Nor  craryc)
- -3HaIIH Ha OnTI4qKH  HeBpI,lTHc: 3aMaTeH  nu,4, ry6er+,e  Ha ErI4AoT
- -3HarIH Ha cpqeBa  auc$yHr&lt;quja  (uaualeua  Spaxquja  uaL uc$pran'e): santop,  HenpHJarHoor  Bo rp arr4T  e, 3 a[I  eM ereH  o cr, 6 or Ka, fi ulnr4T arlplu
- -HlrcKo rrJrr{ B}rcoKo HHBo Ha vHcy;tr4H  Bo KpBTa (xopnrou  rcoj ro pefyJrupa  HI{Boro  ua uertep eo npnra)
- -HucKo HHBo Ha r4*cynprH I-{ nenrzg Bo KpBTa  ($ynxquja  ua naunpeacor)
- -HeHaAejna  crupr

## CneAnune  Apyru  HecaKaHH 4ejcrna  ce npnjaneHlr  co Herlo3Hara 3aqecreHocr  (ue *roxe ga ce rrpoueHH oA AocrarlHure  rloAarouI{):

- -3Harlr4 ua guc$yunyuja  ua cprlero (norraopHa  4uc$yrucquja):  orextuaro AHIIreBe,  Harlop npl4 MgpyBarie,  HcnpaBunHo  qyKame  Ha cplrero, Henpnjaruocr  Bo rpaAHTe, 3alrleMereHocr, 6olrca, ilAIIIIHTA\uvr,  [peKyMepHO  MOKpeIbe, OTeKyBaIr,e  Ha CTaIIanaTa, fJIyx(AOBIITe  I{ cToMztKoT.

## Ilpujanynalbe  HecaKaHn  qejcrna

Axo :a6ele)Kure KaKBo 6zlro secarcauo  4ejcrno,  rpe6a Aa fo  I43BecrI4Te Barulror  AoKTop  HnI'r $apnraqenr.  Toa ro BKJryrryBa H ceKoe Mo)KHo FIecaKaHo  4ejcrno [rro He e HaBeAeHo Bo oBa yllarcrBo. HecaxaHure  4ejcrna oA neKoBHTe Mo)Kere Aa n4 npnjanltre n so HaquoHzlllHttor  IIeHrap 3a $apnaaroerlrrrJlaHrra npu AreHqaj ura 3a JreI(oBH  H MeAHL{HHcKH  cpeAcrBa  (yl. ,,Cn.  Kupun  u Meloguj" 6p.  54, Kar  1)  vlru  no  eJreKrpoHcKH rrar  npeKy ne6-crpauuqara  Ha AreHqlajara http:llmalmed.gov,mk/.  Co npr,rjanynarre  Ha HecaKaHure  Aejcrsa  Mo)Kere  Aa  ilplzAoHecere  3a ilporleHara  na 6es6eAHocra  Ha onoj lex. -

## 5. Kano Aa ro  qyBare  Nilotinib  Pharmascience

- -He ynorpe6yrajre  ro oeoj JreK rro vcreKor  Ha poKor  naynorpe6a r&lt;oj e nare4eu Ha rcyrajara  z ua 6lucrepor  no EXP. Poxor Ha ynorpe6a ce oAHecyBa  Ha nocneAHuor  AeH o4 roj l\4eceq,
- -Llynajre  ro onoj JIeK rIoAaJIeKy  oA BI{A I'r  4o$ar  Ha  Aeqa.
- -Onoj JIeK He 6apa noce6uI4  ycJIoBH  Ha  r{yBarbe.
- -He ro Kopr{crere onoj JIeK aKo sa6erexnre  .qeKa IraKyBa}bero e olrlTereHo  rrnI4 rIoKzDKyBa 3Harrn  Ha MaHhtryJI  aunia.
- He  Qpirajre  HIIKaKBH JIeKoBH Bo ornaAHa BoAa $aprr.raqenr  KaKo  Aa rn $pnrare  JleKoBI4Te IrITo r{Jrr,r  Ac}MarxeH  orrla.q.  llpaurajre  ro Baruuor nose(e  He fH KopI{crI,ITe. Onne  naepnn rte -помогнат да се заштити животната средина.
- pMaIIru 6.

Ceroja rBpAa Karrcyna  oa 150 ffrg coAp)Krr 150 mg nilotinib  (rcano xu4poxJroprzA  guxugpar). Ocranarzre cocroj xu ce:

Co4pxuHa Ha Kancynara: Jlaxtoga MoHoxr4Apar, KpocnoBaAoH Trrrr A (81202), KoJrouAeH 6esBoAeH  cvtvr\kryM (E551), MarHe3rryM  creapar (8470b)

O6eusra Ha KancyJla: Xunpoueroza  (8464),  npoqucreHa  BoAa, Kapareuau (F.407), uarpnyu xrlopaA  (E508), epI4rpo3LIH  (Elit7), )r(erre3o oKcn.q  xorc (8I72), xele:o oKcrzA  r-pBeH (8172), Tr4TaHr{yM  A}roKct4A  Gi  1 7 1  )

Macru:ro  3a rleqarelie: ITleran (E904),  npoilr{JreH fJrrrKoJr (E1520), Harpr,ryM  xH.qpoKcHA (E525),  rIpH )Kene3eH oKurA  @172)

Bu4ere  rel  2, "Nilotinib Pharmascienoe  coAp)Krr  JraKro3a u uurpvrywr"  .

Cexoja rBpAa  Karlcynet o1200 mg coAp)rs4  200 mg nilotinib  (nar&lt;o  xz4poxJroprzA  anxuapa'r). Ocrauarure cocrojxn ce:

Co4pxuHa Ha Kancynara:  Jlanro:a MoHoxr4Apar, KpocnoBHAoH  rtrrr A (81202),  KonoHAeH 6eseo4eH crrnr4ur,ryM (E551), MarHe3HyM  creapar (F.470b)

O6sHsKa  Ha KarcyJla: Xnnpoue,uoza  (8464),  npoarr4creHa  BoAa, KaparenaH  (E407), narpuynr xrropuA (E508), )r(erre3o oKcH.4 &gt;tiorn  (E172),  ruraunyu Ar4oKcHA  (E171)

Macrulo  3a rreqarelbo: ILIelan  (E904), nporr,rJreH  rJrrrKoJr  (81520),  HarpHyM  xnApoKcr4A (8525),  IlpH x(erre3eH oKcHA  G,f7  2)

Brz4ere  Aen 2, "Nilotinib Pharmascience coAplrtIa raKTo3a".

## Karco lr:r.lteaa Nilotinib Pharmascience  u coApxuHa  Ha rraKyBarbero

Nilotirrib Pharmascience 150 mg ce Bo BrrA Ha rrpBeHn (npu6"umrHa  AoJrlr(uHa  19,3 rnrn), co rIpH xopt43oHTrrneH KancyJru  ce [oJrHrz co 6el Ao  ]r(oJrreHrzKrrB  npaB. HenposHpHn  TBpArl KarrcyJfir,  foJreMVHa  I orrrer{aroK  ,,150  mg" Ha reJroro.  TnpAnre

Nilotinib Pharmascience  200 mg ce Bo rlr4A Ha cBerJro  x(oJrrlr Henposr{pHr4  rBpAH  KancyJrrz (xancynu), roleMzHa 0 (npu6naxHa  AonxorHa  21  ,4  mm), co rIpH xopa3oHTuLrreH  orrreqarorc  ,,200  mg" Ha reJroro, TnpArare KancyJTH  ce rroJrHH  co 6el Ao  )r(onreHnKaB npaB.

TspAale  KaIIcyJIII Nilotinib Pharmascience  oA 150 rng ce AocrarrHa  narco 28 KarrcyJru  TBpAH (6nacrep 4 x7)lxyruja

TnpAa:re  Kancyrll4 Nilotinib Phannascien  ce 200 mg ce  AocranHu  rcarco 28 Kancyrn rBpAr{  (6nracrep  4 x 7)lxyrnja

## Hocuren  Ha o4o6penr4e  3a craBarbe Bo rrpoMer

lpymrn  o : a rproeuj a 14 y c rry rH ZHO -I4EAI4KC  Aooen yr. JopaaH XaquxoHcraHTr4HoB  -  IJnuor 6p.19-5 1000 Cxonje,

P. Cer;epna  Marce4oHaja

## flpouano4ure.rr

PharOS  MT Ltd. HF62X, Hal Far Industrial  Estate Birzebbugia BBG3000

Mama

## PharOS  Pharmaceutical  Oriented  Serryices Ltd.

Lesvou  Street  End Thesi Loggos  Industrial  Zone Metamorfo:;si,144  52 fpquja

Haquu Ha ra3AaBarbe  Ha Jrenor: Jlexol ee zr3raBa

BO anTeKa caMo Ha

Ona ynarcrBo  rrocJreAeH  rrar e peBuArrparo  ro

<!-- image -->

## lercennpu2024

## Bpoj na o4o6penue  3a craBalbe  Ha JreK Bo rlpoMer:

<!-- image -->